Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
토요일, 8월 29

Celularity Inc

CELUNASDAQ
Trade with Public
Trade with Public
$1.58
-0.52-24.76%
가까이에: Aug 28, 5:00 PM EST
$1.49
-0.09-5.7%
시간외: 7:59 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Celularity Analyst Price Targets

Wall Street analyst price targets and consensus rating for Celularity (CELU).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$6Upside to Avg. PT+302.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2025WBB SecuritiesSteve BrozakUpgradeHold→Buy$6
Aug 18, 2025WBB SecuritiesSteve BrozakInitiateSpeculative Buy$6

Analyst Ratings News

PRO
WBB Securities Upgrades Celularity to Buy, Maintains Price Target to $6

WBB Securities analyst Steve Brozak upgrades Celularity (NASDAQ:CELU) from Hold to Buy and maintains the price target from $6 to $6.
Benzinga Newsdesk

PRO
WBB Securities Initiates Coverage On Celularity with Speculative Buy Rating, Announces Price Target of $6

WBB Securities analyst Steve Brozak initiates coverage on Celularity (NASDAQ:CELU) with a Speculative Buy rating and announces Price Target of $6.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023

Benzinga Insights

Amazon To Rally Around 29%? Here Are 10 Other Analyst Forecasts For Monday

Barclays cut the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $140 to $130. Barclays analyst Ross Sandler maintained an Overweight rating. Amazon shares fell 1.2% to $101.06 in pre-market trading.
Lisa Levin

PRO
Morgan Stanley Downgrades Celularity to Underweight, Lowers Price Target to $1

Morgan Stanley analyst Jeffrey Hung downgrades Celularity (NASDAQ:CELU) from Equal-Weight to Underweight and lowers the price target from $5 to $1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Celularity, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celularity (NASDAQ:CELU) with a Buy and lowers the price target from $15 to $2.5.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved